Evidence map›Paper›PMID 36444331›Full record

ArticleJACC. Asia2022

Effect of Atorvastatin on Serial Changes in Coronary Physiology and Plaque Parameters.

Cheol Hyun Lee, Jongmin Hwang, In-Cheol Kim, Yun-Kyeong Cho, Hyoung-Seob Park, Hyuck-Jun Yoon, Hyungseop Kim, Seongwook Han, Seung-Ho Hur, Kwon-Bae Kim and 7 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in JACC. Asia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT01946815. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01946815 phase3completed

Phase 3 Study of Effect of ATorvastatin on Fractional Flow Reserve in Coronary Artery Disease

Ran2013Enrolled119Registered outcomes9Posted comparisons0ConditionsCoronary Artery DiseaseArmsAtorvastatin
Open the trial in the graph
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology · 2025
    Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 5 institutions in 1 country.

Cheol Hyun LeeDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Jongmin HwangDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
In-Cheol KimDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Yun-Kyeong ChoDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Hyoung-Seob ParkDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Hyuck-Jun YoonDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Hyungseop KimDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Seongwook HanDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Seung-Ho HurDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Kwon-Bae KimDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Jin Young KimDepartment of Radiology, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Jin-Wook ChungDivision of Cardiology, Department of Internal Medicine, Keimyung University Daegu Dongsan Hospital, Daegu, Republic of Korea.
Joo Myung LeeDivision of Cardiology, Department of Internal Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Joon-Hyung DohDepartment of Medicine, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea.
Eun-Seok ShinDepartment of Internal Medicine, Ulsan University Hospital, Ulsan, Republic of Korea.
Bon-Kwon KooDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul, Republic of Korea.
Chang-Wook NamDivision of Cardiology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea.
Keimyung University · KRInje University Ilsan Paik Hospital · KRSamsung Medical Center · KRSeoul National University Hospital · KRUlsan University Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The effects of statin on coronary physiology have not been well evaluated. Objectives: The authors performed this prospective study to investigate changes in coronary flow indexes and plaque parameters, and their associations with atorvastatin therapy in patients with coronary artery disease (CAD). Methods: Ninety-five patients with intermediate CAD who received atorvastatin therapy underwent comprehensive physiological assessments with fractional flow reserve (FFR), coronary flow reserve, index of microcirculatory resistance, and intravascular ultrasound at the index procedure, and underwent the same evaluations at 12-month follow-up. Optimal low-density lipoprotein cholesterol (LDL-C) was defined as LDL-C <70 mg/dL or ≥50% reduction from the baseline. The primary endpoint was a change in the FFR. Results: Baseline FFR, minimal lumen area, and percent atheroma volume (PAV) were 0.88 ± 0.05, 3.87 ± 1.28, 55.92 ± 7.30, respectively. During 12 months, the percent change in LDL-C was -33.2%, whereas FFR was unchanged (0.87 ± 0.06 at 12 months; Conclusions: In patients with CAD, atorvastatin did not change FFR despite a decrease in the PAV. However, in patients who achieved the optimal LDL-C target level with atorvastatin, the FFR had significantly increased with decrease of the PAV. (Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease [FORTE]; NCT01946815).

Indexed as

CAD, coronary artery diseaseCFR, coronary flow reserveFFR, fractional flow reservefractional flow reserveIMR, index of microcirculatory resistanceintermediate coronary artery diseaseIVUS, intravascular ultrasoundLDL-C, low-density lipoprotein cholesterolLLT, lipid-lowering therapyMLA, minimal lumen areaOR, odds ratioPa, proximal aortic pressurePAV, percent atheroma volumePd, distal coronary pressurestatin therapyTAV, total atheroma volumeTmn, mean transit timeVH, virtual histology

Identifiers

PMID36444331
PMCPMC9700034
OpenAlexW4308037377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.